Taking people in Hollandia4. fázis
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial
Key facts
- Where
- Amsterdam, HollandiaSee the site
- Phase
- 4. fázis
Where in Hollandia
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Trial code
- EU 2023-505884-35-00
- Record updated
- 2026. június 17.
- Original description
The effect of continued LA-SSA use on the absorbed dose in tumor lesions during PRRT.Read full original descriptionShow less
The effect of continued LA-SSA use on the absorbed dose in tumor lesions during PRRT.
Inclusion: Age ≥ 18 years; Able to provide spoken and written informed consent for the trial; Histopathological confirmed neuroendocrine tumor; Fulfill the clinical criteria for PRRT; At least one soft tissue lesion > 2 cm; Aimed administered activity of 7400 MBq; ECOG score (performance status) 0-2.
Exclusion: Not possible to discontinue LA-SSA for 4-6 weeks; Use of short-acting somatostatin analogues; Inability to comply to the study procedures; Factors that might affect the biodistribution (for example, indication for furosemide directly after PRRT infusion, limited fluid intake, any renal catheters, etc.); Pregnancy and lactating female patients.